Stay updated with breaking news from Urinary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Some 79 percent of the patients receiving the new combination of cefepime and enmetazobactam were successfully treated for their illness, as opposed to 58.9 percent of those receiving the conventional treatment of piperacillin and tazobactam.
Dust plumes observed being ‘pushed’ into interstellar space by intense starlight
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) said that the U.S. Food and Drug Administration approved a label expansion for Oxlumo (lumasiran), an RNAi therapeutic administered via
Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinenceENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE)
New branding reflects Company's vision to be the leader in the treatment of Stress Urinary Incontinence in WomenCompletion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results